These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 28075040)

  • 1. N-acetyl-seryl-aspartyl-lysyl-proline mediates the anti-fibrotic properties of captopril in unilateral ureteric obstructed BALB/C mice.
    Chan GCW; Wu HJ; Chan KW; Yiu WH; Zou A; Huang XR; Lan HY; Lai KN; Tang SCW
    Nephrology (Carlton); 2018 Apr; 23(4):297-307. PubMed ID: 28075040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-Acetyl-seryl-aspartyl-lysyl-proline Alleviates Renal Fibrosis Induced by Unilateral Ureteric Obstruction in BALB/C Mice.
    Chan GC; Yiu WH; Wu HJ; Wong DW; Lin M; Huang XR; Lan HY; Tang SC
    Mediators Inflamm; 2015; 2015():283123. PubMed ID: 26508815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of N-acetyl-seryl-aspartyl-lysyl-proline in the antifibrotic and anti-inflammatory effects of the angiotensin-converting enzyme inhibitor captopril in hypertension.
    Peng H; Carretero OA; Liao TD; Peterson EL; Rhaleb NE
    Hypertension; 2007 Mar; 49(3):695-703. PubMed ID: 17283252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolyl oligopeptidase is involved in release of the antifibrotic peptide Ac-SDKP.
    Cavasin MA; Rhaleb NE; Yang XP; Carretero OA
    Hypertension; 2004 May; 43(5):1140-5. PubMed ID: 15037553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-acetyl-seryl-aspartyl-lysyl-proline attenuates renal inflammation and tubulointerstitial fibrosis in rats.
    Wang M; Liu R; Jia X; Mu S; Xie R
    Int J Mol Med; 2010 Dec; 26(6):795-801. PubMed ID: 21042772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The anti-inflammatory peptide Ac-SDKP is released from thymosin-β4 by renal meprin-α and prolyl oligopeptidase.
    Kumar N; Nakagawa P; Janic B; Romero CA; Worou ME; Monu SR; Peterson EL; Shaw J; Valeriote F; Ongeri EM; Niyitegeka JM; Rhaleb NE; Carretero OA
    Am J Physiol Renal Physiol; 2016 May; 310(10):F1026-34. PubMed ID: 26962108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of N-acetyl-seryl-aspartyl-lysyl-proline on DNA and collagen synthesis in rat cardiac fibroblasts.
    Rhaleb NE; Peng H; Harding P; Tayeh M; LaPointe MC; Carretero OA
    Hypertension; 2001 Mar; 37(3):827-32. PubMed ID: 11244003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal release of N-acetyl-seryl-aspartyl-lysyl-proline is part of an antifibrotic peptidergic system in the kidney.
    Romero CA; Kumar N; Nakagawa P; Worou ME; Liao TD; Peterson EL; Carretero OA
    Am J Physiol Renal Physiol; 2019 Jan; 316(1):F195-F203. PubMed ID: 30403163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension.
    Rasoul S; Carretero OA; Peng H; Cavasin MA; Zhuo J; Sanchez-Mendoza A; Brigstock DR; Rhaleb NE
    J Hypertens; 2004 Mar; 22(3):593-603. PubMed ID: 15076166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin converting enzyme inhibitor but not angiotensin receptor blockade or statin ameliorates murine adriamycin nephropathy.
    Tang SC; Leung JC; Chan LY; Eddy AA; Lai KN
    Kidney Int; 2008 Feb; 73(3):288-99. PubMed ID: 18033243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thymosin β4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis.
    Zuo Y; Chun B; Potthoff SA; Kazi N; Brolin TJ; Orhan D; Yang HC; Ma LJ; Kon V; Myöhänen T; Rhaleb NE; Carretero OA; Fogo AB
    Kidney Int; 2013 Dec; 84(6):1166-75. PubMed ID: 23739235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The anti-inflammatory peptide Ac-SDKP: Synthesis, role in ACE inhibition, and its therapeutic potential in hypertension and cardiovascular diseases.
    Kumar N; Yin C
    Pharmacol Res; 2018 Aug; 134():268-279. PubMed ID: 29990624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-Acetyl-seryl-aspartyl-lysyl-proline inhibits TGF-beta-mediated plasminogen activator inhibitor-1 expression via inhibition of Smad pathway in human mesangial cells.
    Kanasaki K; Koya D; Sugimoto T; Isono M; Kashiwagi A; Haneda M
    J Am Soc Nephrol; 2003 Apr; 14(4):863-72. PubMed ID: 12660320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of exendin-4 on the intrarenal renin-angiotensin system and interstitial fibrosis in unilateral ureteral obstruction mice: Exendin-4 and unilateral ureteral obstruction.
    Le Y; Zheng Z; Xue J; Cheng M; Guan M; Xue Y
    J Renin Angiotensin Aldosterone Syst; 2016 Oct; 17(4):. PubMed ID: 27913661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-acetyl-seryl-aspartyl-lysyl-proline ameliorates the progression of renal dysfunction and fibrosis in WKY rats with established anti-glomerular basement membrane nephritis.
    Omata M; Taniguchi H; Koya D; Kanasaki K; Sho R; Kato Y; Kojima R; Haneda M; Inomata N
    J Am Soc Nephrol; 2006 Mar; 17(3):674-85. PubMed ID: 16452498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigating the antifibrotic potential of N-acetyl seryl-aspartyl-lysyl-proline sequence peptides.
    Ramasamy V; Ntsekhe M; Sturrock E
    Clin Exp Pharmacol Physiol; 2021 Nov; 48(11):1558-1565. PubMed ID: 34347311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP): Potential target molecule in research of heart, kidney and brain.
    Hrenak J; Paulis L; Simko F
    Curr Pharm Des; 2015; 21(35):5135-43. PubMed ID: 26350537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New anti-fibrotic mechanisms of n-acetyl-seryl-aspartyl-lysyl-proline in silicon dioxide-induced silicosis.
    Sun Y; Yang F; Yan J; Li Q; Wei Z; Feng H; Wang R; Zhang L; Zhang X
    Life Sci; 2010 Aug; 87(7-8):232-9. PubMed ID: 20624403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronic angiotensin-converting enzyme inhibition.
    Azizi M; Ezan E; Nicolet L; Grognet JM; Ménard J
    Hypertension; 1997 Nov; 30(5):1015-9. PubMed ID: 9369248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effects of Angiotensin Converting Enzyme Inhibitors (ACE-I) on Human N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) Levels: A Systematic Review and Meta-Analysis.
    Mnguni AT; Engel ME; Borkum MS; Mayosi BM
    PLoS One; 2015; 10(12):e0143338. PubMed ID: 26656271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.